Global Human Microbiota Market Based on Product Type: (Prebiotics, Medical Foods, Supplements) Based on Application: (Therapeutics, Diagnostics) Based on Disease Type: (Obesity, Diabetes, Autoimmune Disorder) by Region and Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2022-2032
- Published date: Feb 2022
- Report ID: 84270
- Number of Pages: 364
- Format:
- keyboard_arrow_up
Human Microbiota Market Overview:
The global Human Microbiota Market is projected to reach a valuation of USD 2265.77 Mn by 2032 at a CAGR of 31.08%, from USD 151.30 Mn in 2022.
The human gut microbiome refers to the community of bacteria that resides in the human gut. The gut microbiome is thought to play a crucial role in human health and disease. The gut microbiome has been linked to various diseases, including obesity, diabetes, and cancer. The gut microbiome is also thought to play a role in human nutrition and metabolism. The gut microbiome is responsible for digestion, vitamin production, and immune system function.
A healthy gut microbiome is important for overall health. It helps digest food, provides energy, and protects against infection. A balanced gut microbiome also helps keep the immune system strong. It can even play a role in mood and mental health.
Global Human Microbiota Market Revenue (USD Mn), 2021–2031:
One of the primary aspects fueling the revenue growth of the human microbiome market is its increased use for drug development. This market is expected to expand significantly due to the development of human microbiome-based tests for early illness detection and diagnosis, as well as a surge in consumer interest towards human microbiome therapeutics development. This industry is further influenced by an increase in funding initiatives and government programmes to promote drug research, as well as increased attempts to discover novel drugs by pharmaceutical corporations. Furthermore, booming geriatric populations, increased biotechnology and biopharmaceutical industry investments, as well as a greater number of research & development activities are all elements expected to benefit the human microbiome market. Furthermore, a surge in collaborations between public-private organizations are slated to lead to profitable opportunities for market players over the forecast period.
On the other hand, respective government body regulations, a lack of industry experience, and insufficient research are factors expected to potentially hinder this market’s economic growth trajectory. The human microbiome market is expected to face challenges in proving the causal link between dysbiosis and illnesses.
With a number of small innovative players in this market, there are a number of high-growth opportunities for key stakeholders to acquire companies to study microbiomes in the hopes of discovering new drugs and drug targets for a variety of indications, including obesity, liver disorders, diabetes, and metabolic disorders. With well-organized research & development techniques, several market leaders are now more focused on strategic collaborations and partnerships to expand their product pipelines and existing portfolios.
In the areas of COVID-19, Inflammatory Bowel Disease (IBD), clostridium difficile colitis, Crohn’s disease, and diabetes, microbiome therapies have a wide range of applications. Growing research activities by concerned institutes aimed at discovering additional therapeutic uses of the human microbiome, are expected to continue to propel the progression of this market forward.
Key Market Players:
This research report on the global human microbiota market includes major company profiles such as:
- ENTEROME
- Yakult
- DuPont de Nemours Inc.
- ViThera Pharmaceuticals Inc.
- Second Genome Inc.
- Microbiome Therapeutics LLC
- Vedanta Biosciences Inc.
- Osel Inc.
- Merck Sharp & Dohme Corp
- Seres Therapeutics
- Synthetic Biologics Inc
- Synlogic
- 4D pharma plc
- Metabogen AB
- Ritter Pharmaceuticals
- Symberix
- Symbiotix Biotherapies Inc.
Detail Segmentation:
Segmentation of Global Human Microbiota Market is Based on Product Type, Application, Disease Type, and Region
Based on Product Type:
- Probiotics
- Prebiotics
- Medical Foods
- Supplements
- Other Product Types
Based on Application:
- Therapeutics
- Diagnostics
Based on Disease Type:
- Obesity
- Diabetes
- Autoimmune Disorder
- Metabolic & Gastrointestinal Disorders
- Cancer
- Other Disease Types
Based on Regions:
- North America
- Europe
- Asia Pacific
- South America
- MEA
For the Human Microbiota Market research study, the following years have been considered to estimate the market size:
Attribute Report Details Historical Years
2016-2020
Base Year
2021
Estimated Year
2022
Short Term Projection Year
2028
Projected Year
2023
Long Term Projection Year
2032
Report Coverage
Competitive Landscape, Revenue analysis, Company Share Analysis, Manufacturers Analysis, Volume by Manufacturers, Key Segments, Key company analysis, Market Trends, Distribution Channel, Market Dynamics, COVID-19 Impact Analysis, strategy for existing players to grab maximum market share, and more.
Regional Scope
North America, Europe, Asia-Pacific, South America, Middle East & Africa
Country Scope
United States, Canada and Mexico, Germany, France, UK, Russia and Italy, China, Japan, Korea, India and Southeast Asia, Brazil, Argentina, Colombia etc.Saudi Arabia, UAE, Egypt, Nigeria and South Africa
- ENTEROME
- Yakult
- DuPont de Nemours Inc.
- ViThera Pharmaceuticals Inc.
- Second Genome Inc.
- Microbiome Therapeutics LLC
- Vedanta Biosciences Inc.
- Osel Inc.
- Merck Sharp & Dohme Corp
- Seres Therapeutics
- Synthetic Biologics Inc
- Synlogic
- 4D pharma plc
- Metabogen AB
- Ritter Pharmaceuticals
- Symberix
- Symbiotix Biotherapies Inc.
- settingsSettings
Our Clients
Single User
$5,999
$2,999
USD / per unit
save 50% |
Multi User
$7,999
$3,499
USD / per unit
save 55% |
Corporate User
$12,999
$4,499
USD / per unit
save 65% | |
---|---|---|---|
e-Access | |||
Data Set (Excel) | |||
Company Profile Library Access | |||
Interactive Dashboard | |||
Free Custumization | No | up to 10 hrs work | up to 30 hrs work |
Accessibility | 1 User | 2-5 User | Unlimited |
Analyst Support | up to 20 hrs | up to 40 hrs | up to 50 hrs |
Benefit | Up to 20% off on next purchase | Up to 25% off on next purchase | Up to 30% off on next purchase |
Buy Now ($ 2,999) | Buy Now ($ 3,499) | Buy Now ($ 4,499) |